​
​

Enanta Pharmaceuticals (ENTA) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Enanta Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$79.20M

Latest Revenue (Q)

$17.97M

Main Segment (Y)

Royalty

Main Geography (Y)

Royalty

Enanta Pharmaceuticals Revenue by Period

Enanta Pharmaceuticals Revenue by Year

DateRevenueChange
2023-09-30$79.20M-8.07%
2022-09-30$86.16M-11.24%
2021-09-30$97.07M-20.74%
2020-09-30$122.47M-40.31%
2019-09-30$205.20M-0.69%
2018-09-30$206.63M100.97%
2017-09-30$102.81M16.48%
2016-09-30$88.27M-45.13%
2015-09-30$160.88M236.98%
2014-09-30$47.74M48.94%
2013-09-30$32.05M-23.15%
2012-09-30$41.71M-0.42%
2011-09-30$41.88M83.99%
2010-09-30$22.76M-

Enanta Pharmaceuticals generated $79.20M in revenue during NA 2023, up -8.07% compared to the previous quarter, and up 38.33% compared to the same period a year ago.

Enanta Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-06-30$17.97M5.38%
2024-03-31$17.05M-5.27%
2023-12-31$18.00M-4.91%
2023-09-30$18.93M0.21%
2023-06-30$18.89M6.16%
2023-03-31$17.80M-24.55%
2022-12-31$23.59M16.09%
2022-09-30$20.32M4.30%
2022-06-30$19.48M4.08%
2022-03-31$18.72M-32.31%
2021-12-31$27.65M17.28%
2021-09-30$23.57M9.02%
2021-06-30$21.62M7.41%
2021-03-31$20.13M-36.58%
2020-12-31$31.74M34.33%
2020-09-30$23.63M26.69%
2020-06-30$18.65M-32.46%
2020-03-31$27.62M-47.46%
2019-12-31$52.57M2.45%
2019-09-30$51.31M15.66%
2019-06-30$44.37M11.95%
2019-03-31$39.63M-43.29%
2018-12-31$69.89M3.99%
2018-09-30$67.20M17.36%
2018-06-30$57.26M30.00%
2018-03-31$44.05M15.59%
2017-12-31$38.11M-49.81%
2017-09-30$75.93M910.88%
2017-06-30$7.51M-16.16%
2017-03-31$8.96M-14.00%
2016-12-31$10.42M-18.88%
2016-09-30$12.84M-8.13%
2016-06-30$13.98M7.49%
2016-03-31$13.00M-73.16%
2015-12-31$48.45M236.05%
2015-09-30$14.42M24.29%
2015-06-30$11.60M-79.78%
2015-03-31$57.37M-25.98%
2014-12-31$77.50M2838.87%
2014-09-30$2.64M-93.73%
2014-06-30$42.05M1846.81%
2014-03-31$2.16M141.88%
2013-12-31$893.00K-33.80%
2013-09-30$1.35M-18.19%
2013-06-30$1.65M37.88%
2013-03-31$1.20M-95.71%
2012-12-31$27.86M1399.41%
2012-09-30$1.86M-26.91%
2012-06-30$2.54M-93.05%
2012-03-31$36.56M4834.55%
2011-12-31$741.00K100.00%
2011-09-30--

Enanta Pharmaceuticals generated $17.97M in revenue during Q3 2024, up 5.38% compared to the previous quarter, and up 100.99% compared to the same period a year ago.

Enanta Pharmaceuticals Revenue Breakdown

Enanta Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceSep 23Sep 21Sep 20Sep 19Sep 18
Royalty$78.20M$97.07M$122.47M$205.20M$191.63M
License$1.00M----
Milestone----$15.00M

Enanta Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Sep 23: Royalty (98.74%), and License (1.26%).

Quarterly Revenue by Product

Product/ServiceMar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 19Jun 19Mar 19Dec 18Sep 18Jun 18
Royalty$17.05M$18.00M$18.93M$18.89M$17.80M$22.59M$51.31M$44.37M$39.63M$69.89M$67.20M$57.26M
License-----$1.00M------
Milestone-----------$15.00M

Enanta Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Royalty (100.00%).

Enanta Pharmaceuticals Revenue Breakdown by Country

Annual Revenue by Country

CountrySep 21Sep 20Sep 19Sep 18
Royalty$97.07M$122.47M$205.20M$191.63M
Milestone---$15.00M

Enanta Pharmaceuticals's latest annual revenue breakdown by geography, as of Sep 21: Royalty (100.00%).

Enanta Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
ENTAEnanta Pharmaceuticals$79.20M$17.97M
MRUSMerus$43.95M$11.77M
HOWLWerewolf Therapeutics$19.94M$1.14M
RVMDRevolution Medicines, Inc. Warrant$11.58M-
IKNAIkena Oncology$9.16M-
STOKStoke Therapeutics$8.78M$4.89M
KRONKronos Bio$6.29M$2.37M
CRNXCrinetics Pharmaceuticals$4.01M-
IPSCCentury Therapeutics$2.23M$791.00K
INBXInhibrx Biosciences$1.80M-
LYELLyell Immunopharma$130.00K$34.00K
DSGNDesign Therapeutics--
CGEMCullinan Oncology--
CCCCC4 Therapeutics--
MLYSMineralys Therapeutics--
GLUEMonte Rosa Therapeutics-$4.70M
EWTXEdgewise Therapeutics--

ENTA Revenue FAQ

What is Enanta Pharmaceuticals’s yearly revenue?

Enanta Pharmaceuticals's yearly revenue for 2023 was $79.2M, representing a decrease of -8.07% compared to 2022. The company's yearly revenue for 2022 was $86.16M, representing a decrease of -11.24% compared to 2021. ENTA's yearly revenue for 2021 was $97.07M, representing a decrease of -20.74% compared to 2020.

What is Enanta Pharmaceuticals’s quarterly revenue?

Enanta Pharmaceuticals's quarterly revenue for Q3 2024 was $17.97M, a 5.38% increase from the previous quarter (Q2 2024), and a -4.88% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $17.05M, a -5.27% decrease from the previous quarter (Q1 2024), and a -4.16% decrease year-over-year (Q2 2023). ENTA's quarterly revenue for Q1 2024 was $18M, a -4.91% decrease from the previous quarter (Q4 2023), and a -23.67% decrease year-over-year (Q1 2023).

What is Enanta Pharmaceuticals’s revenue growth rate?

Enanta Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -18.41%, and for the last 5 years (2019-2023) was -61.40%.

What are Enanta Pharmaceuticals’s revenue streams?

Enanta Pharmaceuticals's revenue streams in p 23 are Royalty, and License. Royalty generated $78.2M in revenue, accounting 98.74% of the company's total revenue, down -19.44% year-over-year. License generated $1M in revenue, accounting 1.26% of the company's total revenue

What is Enanta Pharmaceuticals’s main source of revenue?

For the fiscal year ending Sep 23, the largest source of revenue of Enanta Pharmaceuticals was Royalty. This segment made a revenue of $78.2M, representing 98.74% of the company's total revenue.